These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2007-001174-81 RANDOMIZED MULTICENTER PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIOTHERAPY AND WITH OR WITHOUT ERLOTINIB 2014-01-31 due-trials
Reported results 2007-002115-59 CHIMIOTHERAPIE AVEC OU SANS ANTICOAGULATION PREVENTIVE DANS LES CANCERS DU PANCREAS METASTATIQUES 2012-11-06 due-trials
Reported results 2007-002116-25 chimiothérapie d'induction par Erbitux-Taxotère-Cisplatine-5FU (ETPF) dans les carcinomes épidermoides de l'oropharynx de stade III-IV opérables 2013-10-30 due-trials
Not reported 2007-002797-56 Phase III study of an optimized chemotherapy + Avastin strategy +/- Tarceva in metastatic colorectal cancer. 2014-12-10 due-trials
Reported results 2007-004806-28 An Open-label Phase II Clinical trial of Panitumumab in Combination with Irinotecan for Patients with Advanced Metastatic Colorectal Cancer without KRAS mutation (Wild type) in third line chemotherapy... 2012-06-30 due-trials
Exempt, with results 2008-005702-39 Phase I/II study of Induction Chemotherapy with weekly RAD001, Carboplatine and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) 2013-01-31 not-yet-due
Ongoing 2009-010384-16 A Phase III randomized trial investigating the duration of adjuvant therapy with the modified FOLFOX 6 regimen (3 versus 6 months) for patients with stage III colon cancer. not-yet-due
Ongoing 2009-018058-44 Proof-of-concept phase II study to evaluate the anti-tumoractivity of sorafenib along with pathological and molecularchanges in tumor samples from patients with resectable hepatocellular carcinoma. not-yet-due
Not reported 2012-001098-94 A randomized phase II double-blind trial of sunitinib versus placebo in combination with lanreotide in patients with progressive advanced/metastatic midgut carcinoid tumors 2019-11-12 due-trials
Not reported 2013-001463-23 Randomized Phase II Study of Weekly ABI-007 plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients with Metastatic Pancreatic Cancer. 2018-09-13 due-trials
Ongoing 2013-001928-19 Multi-Line Therapy Trial in Unresectable Wild-Type KRAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III study. not-yet-due
Ongoing 2017-002442-72 RECIST 1.1 and iRECIST evaluation for patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab. A GERCOR open-label phase II study NIPICOL C17-01 not-yet-due
Ongoing 2017-003185-27 A non-comparative randomized 2:1 phase II study of docetaxel, cisplatin, and 5-fluorouracil in combination or not with atezolizumab in patients with metastatic or unresectable locally advanced squamou... not-yet-due
Other 2017-004548-40 A randomized non-comparative phase II study of Maintenance therapy with OSE2101 vaccine alone or in combination with nivolumab, or FOLFIRI after induction therapy with FOLFIRINOX in patients with loca... not-yet-due
Ongoing 2018-004712-22 Peri-operative association of immunotherapy (pre-operative association of nivolumab and ipilimumab, post-operative nivolumab alone) in localized microsatellite instability (MSI) and/or deficient misma... not-yet-due
Ongoing 2019-004366-18 MAZEPPA: Phase II PRODIGE-GERCOR study to evaluate MAintenance therapy with olaparib or selumetinib plus durvalumab according to BRCAness and KRAS somatic status Personalized in metastatic Pancreatic ... not-yet-due
Other 2020-004366-19 Identification of the optimal combination dosing schedule of nivolumab and ipilimumab in patients with dMMR and/or MSI metastatic colorectal cancer: A GERCOR open-label, randomized, non-comparative, t... not-yet-due
Not reported 2020-004636-25 A phase II study to evaluate the rate of cardiovascular events during trifluridine/tipiracil +/-oxaliplatin treatment in colorectal/oesogastric adenocarcinoma patients that have experienced a past e... 2022-11-16 due-trials
Other 2021-005146-15 Nivolumab and ipilimumab in patients with dMMR and/or MSI metastatic colorectal cancer resistant to anti-PD1 monotherapy: An open-label phase II GERCOR trial (NIPIRESCUE) not-yet-due